NZ709215A - Compositions comprising anti-cd38 antibodies and lenalidomide - Google Patents

Compositions comprising anti-cd38 antibodies and lenalidomide

Info

Publication number
NZ709215A
NZ709215A NZ709215A NZ70921513A NZ709215A NZ 709215 A NZ709215 A NZ 709215A NZ 709215 A NZ709215 A NZ 709215A NZ 70921513 A NZ70921513 A NZ 70921513A NZ 709215 A NZ709215 A NZ 709215A
Authority
NZ
New Zealand
Prior art keywords
compositions
antibodies
lenalidomide
kits
disclosed
Prior art date
Application number
NZ709215A
Other languages
English (en)
Inventor
Byron Hann
Martin, Iii
Blake Aftab
Blake Tomkinson
Original Assignee
Sanofi Sa
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Univ California filed Critical Sanofi Sa
Publication of NZ709215A publication Critical patent/NZ709215A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ709215A 2012-12-07 2013-12-06 Compositions comprising anti-cd38 antibodies and lenalidomide NZ709215A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734524P 2012-12-07 2012-12-07
US201361769247P 2013-02-26 2013-02-26
US201361808372P 2013-04-04 2013-04-04
PCT/US2013/073540 WO2014089416A1 (en) 2012-12-07 2013-12-06 Compositions comprising anti-cd38 antibodies and lenalidomide

Publications (1)

Publication Number Publication Date
NZ709215A true NZ709215A (en) 2020-08-28

Family

ID=50884019

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ709215A NZ709215A (en) 2012-12-07 2013-12-06 Compositions comprising anti-cd38 antibodies and lenalidomide

Country Status (31)

Country Link
EP (2) EP3597191A1 (enExample)
JP (2) JP6499971B2 (enExample)
KR (2) KR102193045B1 (enExample)
CN (1) CN105263520B (enExample)
AR (1) AR093844A1 (enExample)
AU (2) AU2013355064B2 (enExample)
BR (1) BR112015012987A2 (enExample)
CA (1) CA2893946A1 (enExample)
CL (2) CL2015001558A1 (enExample)
CY (2) CY1122478T1 (enExample)
DK (1) DK2928495T3 (enExample)
ES (1) ES2731548T3 (enExample)
HR (1) HRP20191034T1 (enExample)
HU (3) HUE044142T2 (enExample)
IL (2) IL239234B (enExample)
LT (2) LT2928495T (enExample)
LU (1) LUC00187I2 (enExample)
MX (2) MX366296B (enExample)
MY (1) MY191601A (enExample)
NL (1) NL301079I2 (enExample)
NZ (1) NZ709215A (enExample)
PH (1) PH12015501263A1 (enExample)
PL (1) PL2928495T3 (enExample)
PT (1) PT2928495T (enExample)
RS (1) RS58829B1 (enExample)
RU (1) RU2698911C2 (enExample)
SG (3) SG11201504315WA (enExample)
SI (1) SI2928495T1 (enExample)
TW (2) TW201919699A (enExample)
UA (1) UA118255C2 (enExample)
WO (1) WO2014089416A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2015195555A1 (en) * 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
JP6802791B2 (ja) 2014-12-04 2020-12-23 ヤンセン バイオテツク，インコーポレーテツド 急性骨髄性白血病の治療のための抗ｃｄ３８抗体
EP4553157A3 (en) 2015-05-20 2025-07-23 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
UA125115C2 (uk) 2015-06-22 2022-01-12 Янссен Байотек, Інк. Спосіб лікування суб'єкта, який має множинну мієлому (мм)
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP7316930B2 (ja) 2016-07-15 2023-07-28 武田薬品工業株式会社 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
CN112739715A (zh) 2018-01-12 2021-04-30 武田药品工业株式会社 抗cd38抗体的皮下给药
KR102286500B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
KR102286499B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 약제학적 조성물
WO2019199135A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
JP7581052B2 (ja) * 2018-04-13 2024-11-12 サムヤン ホールディングス コーポレイション レナリドミドの経口用コーティング錠剤組成物
JP2021518424A (ja) * 2018-04-13 2021-08-02 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 様々な用量のレナリドミドの経口用錠剤組成物
KR20220080044A (ko) 2018-05-16 2022-06-14 얀센 바이오테크 인코포레이티드 암 요법에 사용하기 위한 bcma/cd3 및 gprdc5d/cd3 이중특이성 항체
IL281845B2 (en) * 2018-10-01 2025-06-01 Celgene Corp Combination therapy comprising 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and daratumumab for the treatment multiple myeloma
KR20220002891A (ko) * 2019-03-15 2022-01-07 모르포시스 아게 자가항체-매개 자가면역 질병의 치료를 위한 항-cd38 항체 및 이의 약제학적 조성물
CN113993543B (zh) * 2019-06-10 2024-07-12 武田药品工业株式会社 使用抗cd38抗体的组合疗法
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
IL292181A (en) * 2019-10-31 2022-06-01 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
KR20220159947A (ko) 2019-12-05 2022-12-05 사노피-아벤티스 유.에스. 엘엘씨 피하 투여를 위한 항-cd38 항체의 제형
US20250277051A1 (en) * 2021-08-02 2025-09-04 Hangzhou Unogen Biotech, Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2006068185A1 (ja) * 2004-12-21 2006-06-29 Nippon Kayaku Kabushki Kaisha エポキシ樹脂、エポキシ樹脂組成物及びその硬化物
MX2007011064A (es) * 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
TR201910145T4 (tr) * 2006-09-26 2019-08-21 Genmab As Tümörlerin tedavi edilmesine yönelik anti-CD38 artı kortikosteroidler artı bir kortikosteroid-olmayan kemoterapötik.
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
PT2621531T (pt) * 2010-09-27 2017-03-13 Morphosys Ag Anticorpo anti-cd38 e lenalidomida ou bortezomibe para o tratamento de mieloma múltiplo e linfoma não-hodgkins
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38

Also Published As

Publication number Publication date
EP2928495B1 (en) 2019-03-27
AU2013355064B2 (en) 2018-05-24
EP2928495A4 (en) 2016-05-11
HUE044142T2 (hu) 2019-09-30
TWI670062B (zh) 2019-09-01
IL239234A0 (en) 2015-07-30
CL2018003292A1 (es) 2019-02-01
HK1215536A1 (en) 2016-09-02
IL282542A (en) 2021-06-30
LUC00187I2 (enExample) 2024-07-01
MY191601A (en) 2022-07-01
CY1122478T1 (el) 2021-01-27
HRP20191034T1 (hr) 2019-08-23
SI2928495T1 (sl) 2019-07-31
UA118255C2 (uk) 2018-12-26
BR112015012987A2 (pt) 2017-09-12
TW201919699A (zh) 2019-06-01
EP3597191A1 (en) 2020-01-22
KR102193045B1 (ko) 2020-12-18
DK2928495T3 (da) 2019-06-24
PH12015501263A1 (en) 2015-08-17
AU2018211258A1 (en) 2018-08-16
CN105263520A (zh) 2016-01-20
MX2019008065A (es) 2019-09-23
AR093844A1 (es) 2015-06-24
HUS2000051I1 (hu) 2020-12-28
KR20200143503A (ko) 2020-12-23
PT2928495T (pt) 2019-07-04
RS58829B1 (sr) 2019-07-31
CY2020040I1 (el) 2021-03-12
LTC2928495I2 (lt) 2024-11-25
LT2928495T (lt) 2019-07-10
PL2928495T3 (pl) 2019-09-30
CY2020040I2 (el) 2021-05-05
JP6499971B2 (ja) 2019-04-10
ES2731548T3 (es) 2019-11-15
CA2893946A1 (en) 2014-06-12
SG10201704536PA (en) 2017-07-28
EP2928495A1 (en) 2015-10-14
CN105263520B (zh) 2020-03-13
LTPA2020537I1 (lt) 2020-12-28
HUS2000050I1 (hu) 2020-12-28
RU2698911C2 (ru) 2019-09-02
MX2015007189A (es) 2016-03-21
AU2013355064A1 (en) 2015-07-09
SG10201913783PA (en) 2020-03-30
JP2019070020A (ja) 2019-05-09
RU2015127089A (ru) 2017-01-13
IL239234B (en) 2021-05-31
CL2015001558A1 (es) 2015-10-02
MX366296B (es) 2019-07-04
SG11201504315WA (en) 2015-07-30
JP2016506388A (ja) 2016-03-03
NL301079I2 (nl) 2021-03-29
TW201427663A (zh) 2014-07-16
WO2014089416A1 (en) 2014-06-12
KR20150091165A (ko) 2015-08-07

Similar Documents

Publication Publication Date Title
NZ709215A (en) Compositions comprising anti-cd38 antibodies and lenalidomide
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
PH12021552158A1 (en) Antibodies to icos
MY175418A (en) Compositions comprising anti-cd38 antibodies and carfilzomib
MX2021013665A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
EA202193044A2 (ru) Способы лечения таупатии
MY184628A (en) Afucosylated anti-fgfr2iiib antibodies
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
MX347164B (es) Anticuerpos anti-il-36r.
WO2013056148A3 (en) Scd1 antagonists for treating cancer
EP3054940A4 (en) Compositions and methods for treating non-alcoholic steatohepatitis
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
PH12014502406B1 (en) Anti-il-23p19 antibodies
HK1220155A1 (zh) 治疗癌症的方法
MX2024008826A (es) Composicion para la estimulacion ovarica controlada.
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
EA201592203A1 (ru) Способы лечения таупатии
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
WO2013106460A3 (en) Compositions and methods for treating malignant astrocytomas
WO2014201118A3 (en) Compositions and methods for targeted endometriosis treatment
MX363631B (es) Composiciones y metodos para tratar infecciones bacterianas.

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND LENALIDOMIDE; FILING DATE: 17 JUN 2015; STATUS: REJECTED; KIND CODE: A1 PUBLICATION DATE: 26 JUN 2015; TITLE: COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND LENALIDOMIDE; FILING DATE: 17 JUN 2015; STATUS: REJECTED; KIND CODE: TITLE: COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND LENALIDOMIDE; FILING DATE: 10 DEC 2018; STATUS: REJECTED; KIND CODE: TITLE: COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND LENALIDOMIDE; FILING DATE: 17 APR 2020; STATUS: PROPOSED; KIND CODE:

Effective date: 20200429

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2022 BY CPA GLOBAL

Effective date: 20211022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2023 BY CPA GLOBAL

Effective date: 20221020

ASS Change of ownership

Owner name: SANOFI-AVENTIS U.S. LLC, US

Effective date: 20230419

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, US

Effective date: 20230419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2024 BY CPA GLOBAL

Effective date: 20231019

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241101

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251025